BioCentury | Oct 31, 2020

Data Byte: at $1.9B valuation, Atea leads this week’s IPOs

...which Gilead Sciences Inc. (NASDAQ:GILD) bought for $11.2 billion in 2012, gaining HCV blockbuster Sovaldi sofosbuvir...
BioCentury | Oct 27, 2020

With $1.8B valuation within reach, Sommadossi’s Atea readies ‘mega-IPO’

...which Gilead Sciences Inc. (NASDAQ:GILD) bought for $11.2 billion in 2012, gaining HCV blockbuster Sovaldi sofosbuvir.Institutional...
BioCentury | Oct 23, 2020

Roche in $350M deal with Sommadossi’s Atea for what it believes could be first oral COVID-19 antiviral

...which Gilead Sciences Inc. (NASDAQ:GILD) bought for $11.2 billion in 2012, gaining HCV blockbuster Sovaldi sofosbuvir.For...
BioCentury | May 21, 2020

With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial

...Inc., which Gilead took out for $11.2 billion in 2012, gaining HCV blockbuster therapy Sovaldi sofosbuvir...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

...controversies clouded the roll-out in 2013 of the first highly effective Hepatitis C treatment. Sovaldi sofosbuvir...
...More than three million people in the U.S. are living with HCV, and prior to Sovaldi’s...
...The benefits are becoming apparent outside the U.S. In Egypt, where Gilead’s agreement to license sofosbuvir...
BioCentury | Dec 2, 2019
Company News

Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

...with chemotherapy. Other notable additions to the NRDL include HCV drugs Epclusa sofosbuvir/velpatasvir and Harvoni sofosbuvir/ledipasvir...
BioCentury | Oct 4, 2019
Clinical News

Arbutus scuttles lead HBV capsid inhibitor program

...2011 for $11 billion, obtaining Sovaldi sofosbuvir when that compound was in Phase III testing. Sovaldi...
BioCentury | Aug 28, 2019
Politics & Policy

Aug. 28 P&P Quick Takes: Liver failure warning for HCV drugs; plus FDA guidances and more

...glecaprevir/pibrentasvir from AbbVie Inc. (NYSE:ABBV), Zepatier grazoprevir/elbasvir from Merck & Co. Inc. (NYSE:MRK) and Vosevi sofosbuvir/velpatasvir/voxilaprevir...
BioCentury | Jul 17, 2019
Company News

Gilead CSO McHutchison, two others, out as O’Day reshapes his team

...leadership, Gilead developed the HCV combination regimens that were built off the backbone of Sovaldi sofosbuvir...
BioCentury | Jun 27, 2019
Politics & Policy

June 26 P&P Quick Takes: FDA solicits comments on transparency programs; plus Louisiana’s HCV drug model and more

...Gilead Sciences Inc. (NASDAQ:GILD) subsidiary Asegua Therapeutics LLC to provide an authorized generic of Epclusa sofosbuvir/velpatasvir...
...based on smaller data sets than normally required. Jonathan Block, Associate Editor Epclusa (Brand), sofosbuvir/GS-5816 (Compound #), sofosbuvir/velpatasvir...
Items per page:
1 - 10 of 742